J&J presented the new analysis from three Phase III trials of Caplyta in MDD.

A new medical large language model (LLM) achieved over 91% accuracy in identifying female participants diagnosed with major ...

The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...

The American College of Lifestyle Medicine, or ACLM, released a new expert consensus statement on the role of lifestyle ...

Internet use is part of daily life for many people in work, social interaction, entertainment, shopping, and many other ...

Adjunctive omega-3 therapy failed to improve moderate-to-severe depression more than place ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical ...

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

New TMS biomarkers combined with machine learning accurately classified major depressive disorder. Learn more about this ...